TAIJI GROUP: Received the clinical trial approval notice for Semaglutide injection
TAIJI GROUP's wholly-owned subsidiary Fuling Pharmaceutical Factory recently received approval from the National Medical Products Administration to conduct clinical trials for Semaglutide injection, indicated for type 2 diabetes. This medication is a long-acting GLP-1 receptor agonist that stimulates insulin production, inhibits glucagon secretion, and reduces appetite, assisting in weight management
According to the Zhitong Finance APP, TAIJI GROUP (600129.SH) announced that its wholly-owned subsidiary Taiji Group Chongqing Fuling Pharmaceutical Factory Co., Ltd. (referred to as: Fuling Pharmaceutical Factory) has received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration regarding Semaglutide injection, allowing the product to conduct clinical trials for the indication of type 2 diabetes.
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that can stimulate insulin production, inhibit glucagon secretion, and reduce appetite and food intake, thereby playing an important role in the treatment of type 2 diabetes and assisting in weight management
